Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

This study compared the adverse effects of baricitinib and methotrexate in treating severe alopecia areata and found baricitinib to have a better safety profile, though it was associated with increased cholesterol, triglyceride, and LDL levels.

Isotretinoin can raise CPK levels, so patients need monitoring, especially before surgery.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.